Interferon Alpha-n3

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Dosage

Brand Names

Europe

Czech Republic: Multiferon; Denmark: Multiferon; Estonia: Multiferon; Hungary: Egiferon, Multiferon; Italy: Alfaferone; Latvia: Multiferon; Lithuania: Multiferon; Romania: Alfaferone; Slovakia: Alfaferone, Multiferon; Sweden: Multiferon.

North America

USA: Alferon N.

Drug combinations

Chemistry

Interferon Alpha-n3: A mixture of natural interferon alpha proteins; secreted proteins produced according to information coded by interferon genes and which exert nonspecific antiviral activity at least in homologous cells through cellular metabolic processes involving synthesis of both ribonucleic acid and proteins. Interferons, α- (1988).

Pharmacologic Category

Antineoplastic Agents; Immunostimulants. Biologic Response Modifiers. Antivirals; Interferons. (ATC-Code: L03AB).

Mechanism of action

Inhibits cellular growth, alters state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells.

Therapeutic use

Intralesional treatment of refractory or recurring genital or venereal warts (condylomata acuminata) in patients ≥18 years of age.

Pregnancy and lactiation implications

Safety and efficacy for use during pregnancy not established. Interferon alpha shown to decrease serum estradiol and progesterone levels in humans. Menstrual irregularities and abortion reported in animals. Not recommended during lactation.

Unlabeled use

Contraindications

Hypersensitivity to alpha interferon or any component of the formulation. Anaphylactic sensitivity to mouse immunoglobulin, egg protein, or neomycin.

Warnings and precautions

Hazardous agent. Flu-like symptoms common. Use with caution in severe myelosuppression, or in pre-existing cardiac disease, including unstable angina, uncontrolled heart failure, or arrhythmias. Use with caution in coagulation disorders (such as thrombophlebitis, pulmonary embolism, hemophilia), in diabetes with ketoacidosis, in severe pulmonary disease, or in history of seizure disorder. Contains albumin.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart